Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model

被引:12
作者
Zheng, Chun-Song [1 ]
Wu, Yin-Sheng [1 ]
Bao, Hong-Juan [2 ]
Xu, Xiao-Jie [1 ,3 ]
Chen, Xing-Qiang [1 ]
Ye, Hong-Zhi [1 ]
Wu, Guang-Wen [1 ]
Xu, Hui-Feng [1 ]
Li, Xi-Hai [1 ]
Chen, Jia-Shou [1 ]
Liu, Xian-Xiang [1 ]
机构
[1] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China
[2] Xiamen Med Coll, Dept Pharm, Xiamen 361008, Fujian, Peoples R China
[3] Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China
关键词
Xiao Chai Hu Tang; polypharmacology; cancer; computational pharmacology; CHINESE MEDICINE; CANCER; COMBINATION; DATABASE; NETWORK; AGENTS; DRUGS;
D O I
10.3892/etm.2014.1660
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Xiao Chai Hu Tang (XCHT), a traditional herbal formula, is widely administered as a cancer treatment. However, the underlying molecular mechanisms of its anticancer effects are not fully understood. In the present study, a computational pharmacological model that combined chemical space mapping, molecular docking and network analysis was employed to predict which chemical compounds in XCHT are potential inhibitors of cancer-associated targets, and to establish a compound-target (C-T) network and compound-compound (C-C) association network. The identified compounds from XCHT demonstrated diversity in chemical space. Furthermore, they occupied regions of chemical space that were the same, or close to, those occupied by drug or drug-like compounds that are associated with cancer, according to the Therapeutic Targets Database. The analysis of the molecular docking and the C-T network demonstrated that the potential inhibitors possessed the properties of promiscuous drugs and combination therapies. The C-C network was classified into four clusters and the different clusters contained various multi-compound combinations that acted on different targets. The study indicated that XCHT has a polypharmacological role in treating cancer and the potential inhibitory components of XCHT require further investigation as potential therapeutic strategies for cancer patients.
引用
收藏
页码:1777 / 1783
页数:7
相关论文
共 35 条
  • [1] The role of new agents in the treatment of non-small cell lung cancer
    Bröker, LE
    Glaccone, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (18) : 2347 - 2361
  • [2] Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations
    Broxterman, HJ
    Georgopapadakou, NH
    [J]. DRUG RESISTANCE UPDATES, 2005, 8 (04) : 183 - 197
  • [3] Use of Chinese medicine by cancer patients: a review of surveys
    Carmady, Bridget
    Smith, Caroline A.
    [J]. CHINESE MEDICINE, 2011, 6
  • [4] Non-small-cell lung cancer - Stalemate or progress?
    Carney, DN
    Hansen, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (17) : 1261 - 1262
  • [5] Chan JY, 2009, ANTICANCER RES, V29, P3043
  • [6] Chemical space and biology
    Dobson, CM
    [J]. NATURE, 2004, 432 (7019) : 824 - 828
  • [7] Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    Ferlay, Jacques
    Shin, Hai-Rim
    Bray, Freddie
    Forman, David
    Mathers, Colin
    Parkin, Donald Maxwell
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2893 - 2917
  • [8] Franek KJ, 2005, INT J ONCOL, V26, P217
  • [9] Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus
    Gu, Jiangyong
    Zhang, Hu
    Chen, Lirong
    Xu, Shun
    Yuan, Gu
    Xu, Xiaojie
    [J]. COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2011, 35 (05) : 293 - 297
  • [10] Han GX, 2010, ZHEJIANG J TRADITION, V4, P687